MarginsXMarginsX
Home › Markets › Health Care › IVA

Inventiva S.A. American Depository Shares (IVA)

IVA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.32
-9.78% on the day
Market cap
$784.5M
Small cap
Revenue · 2025
$5.0M
-51.9% on 2024
Net income · 2025
-$391.4M
-7899.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/0001104659-26-040704-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31. Converted from EUR at 0.9048 per USD (today's ECB or Federal Reserve reference rate).

Profile

FieldValue
TickerIVA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryFrance
IPO year2020
SEC CIK0001756594
SEC industry codePharmaceutical Preparations
Incorporated inFrance

Financials · 2025

LineValue
Revenue$5.0M
Net income-$391.4M
Operating income-$155.8M
Net margin-7899.6%
Operating margin-3145.5%
Revenue growth-51.9%
Cash$109.8M
Total assets$275.8M
P/E (computed)Net income was not positive
P/S (computed)158.3×

Reported in EUR; shown in US dollars.

Warning signs

Cash runway
11.4 months
$109.8M cash at December 31, 2025
Share count, 1 year
+102.0%
2024-12-31 to 2025-12-31 · +358.6% over 3 years
Going-concern doubt
Yes
20-F filed April 8, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors raise substantial doubt regarding our ability to continue as a going concern."
20-F 2026-04-08
Cash and burn$109.8M cash; operating cash flow -$29.0M a quarter.Report 2025-12-31
Shares outstanding193,236,978 (2025-12-31); 95,662,391 a year earlier; 42,134,169 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-06-02
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG SA, Paris La Défense, FrancePCAOB Form AP 2026-04-28
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$5.0M-$391.4M-$115.9M$109.8M$66.2M$5.0M20-F 2026-04-08
FY 2021
2021-12-31
Not filed-$49.6MNot filedNot filedNo debt tagsNeeds four quarters20-F 2022-03-11

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-06-02
Latest annual report20-F2026-04-08
Latest quarterly / interim
FORM 6-K
6-K2026-10-06

Source: SEC EDGAR submissions feed, 228 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-3.2%
1 month+28.2%
3 months-20.0%
Year to date-20.9%
1 year-3.7%
From 52-week high-48.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ORICOric Pharmaceuticals Inc.$7.52-4.33%$779.5M
LXRXLexicon Pharmaceuticals Inc.$1.75-2.23%$779.2M
COLLCollegium Pharmaceutical Inc.$25.43+0.43%$790.2M
ARDXArdelyx Inc.$3.07-0.65%$771.7M
IRWDIronwood Pharmaceuticals Inc.$4.85+0.41%$802.9M
OBXObsidian Therapeutics Inc.$12.36-1.59%$763.5M
SNDXSyndax Pharmaceuticals Inc.$9.13-3.39%$821.6M
RIGLRigel Pharmaceuticals Inc.$43.73-1.64%$823.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier